The 20th class of Helios Scholars at TGen have concluded their 2026 internships with a day-long scientific symposium celebrating their accomplishments over the past eight weeks. The symposium marks the finish line for a program designed to help students build practical research skills while working side‑by‑side with TGen scientists and staff. Families, mentors, and community members joined the event to recognize the accomplishments of this year’s Scholars.Continue reading
Author Archive: AZBio
Bear Down Momentum: U of A 2025-26
University of Arizona President Suresh Garimella has released his second annual letter to the university community, detailing how the university advanced its strategic imperatives over the past year while positioning itself for even greater impact in the years ahead.
The letter chronicles a university building extraordinary momentum across every aspect of its mission.
Arizona Medical Technology Projects Receive $600,000 in Funding
Partnership for Economic Innovation Applied Research Centers funding helps six health technology projects move faster from research to marketContinue reading
TGen and City of Hope selected to national team exploring lysosomal dysfunction driving Parkinson’s disease
The Aligning Science Across Parkinson’s (ASAP) grant supports research focused on understanding how impaired cellular waste-clearing systems contribute to Parkinson’s disease
Learn About the 2026 Arizona General Election Candidates and Propositions
Arizona.Vote is the official source for Primary Election and General Election information in Arizona. The Official Results of the 2026 Primary Election will be confirmed on August 8th. Propositions that will be on the November ballot have now been assigned numbers. Early voting for the November 2026 General Election begins on October 7, 2026.
Continue reading
Arizona Bioscience Week – A Decade of Putting Arizona in the Spotlight
Did you know that Arizona was the pioneer in establishing a dedicated statewide bioscience week. Arizona was unique in establishing its week early on, while most other states historically relied on single-day summits or standalone conferences. The structured, multi-day format has gained major traction over the last decade in other states or regions.Continue reading
SuperAging is not simply the opposite of Alzheimer’s disease
A new study reveals that exceptional memory aging cannot be explained simply by low inherited Alzheimer’s disease risk, reinforcing the importance of studying protective pathways directlContinue reading
LaunchAZ Fall Cohort – Bioscience and Healthcare
Up to 15 companies will be selected from the applicant pool to take part in each cohort anchored around key activities in the state. The Fall 2026 Cohort will focus on biotech and health tech and will coincide with Arizona Bioscience Week, kicking off on October 5, 2026. Applications close August 7, 2026.Continue reading
Feedback Sought on Proposals to Reform Pharmaceutical Pricing, Bolster Innovation
On June 16, 2026, Senate Finance Committee Ranking Member Ron Wyden (D-OR) released a request for information on a host of proposals aimed at lowering the cost of prescription drugs, as a part of Senate Democrats’ work to make health care affordable for all Americans. Text of the Request for Information (PDF) Members of the public are encouraged to weigh in with feedback by August 17, 2026.
The request for information focuses on three policy objectives:
- Lowering the price manufacturers charge for prescription drugs
- Lowering out-of-pocket costs for patients
- Fostering biopharmaceutical innovation in areas of unmet need, bolstering domestic clinical trials, and recruiting and maintaining scientific talent
NuvOx Therapeutics Receives FDA Fast Track Designation to NanO₂™ for the Treatment of Acute Ischemic Stroke
TUCSON, AZ, July 15, 2026 — NuvOx Therapeutics, Inc. (“NuvOx Therapeutics”, “NuvOx”, or the “Company”) today announces that its wholly owned subsidiary, NuvOx Pharma LLC, has been granted Fast Track designation for NanO₂™ by the U.S. Food and Drug Administration (“FDA”) for the treatment of adult patients presenting with acute ischemic stroke (“AIS”).